A Study of FB1003 in Healthy and Osteoarthritis Pain Subjects

Summary

The purpose of Part 1 is to evaluate safety and tolerability of FB1003 when given subcutaneously to healthy participants. Blood tests will be done to examine blood exposure, concentration and half-life of FB1003 following administrations. For each participant, the study will last up to about 12 weeks for single ascending dose part, and 18 weeks for multiple ascending dose part, including screening. The purpose of Part 2 is to assess the safety, tolerability, PK and efficacy of SAD of SC administered FB1003 in adult subjects with osteoarthritis (OA) pain.

Timeline

Start

2024-04-07

Primary completion

2026-02-28

Completion

2026-05-30

Drugs

Indications

No indication recorded.